High Sensitivity C-Reactive Protein In Type-2 Diabetes Mallitus Patients with Peripheral Vasculopathy
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 2, Pages 673-679
AbstractBackground: Systemic inflammatory activity has turned out to play a key pathogenic role in vascular atherosclerosis, insulin resistance, and type 2 diabetes mellitus. Inflammatory biomarkers may therefore be a valuable tool for risk evaluation. Among them, the best evidence to date supports the use of high-sensitivity C-reactive protein (hs-CRP) to monitor insulin resistance and cardiovascular risk in diabetic and nondiabetic individuals.
Aims and Objectives: To assess the relation of symptomatic peripheral arterial disease and high sensitivity c-reactive protein in known type 2 diabetes patients and to study the passive smoking as an additional risk factor for peripheral vasculopathy and elevated high sensitivity c-reactive protein.
Materials and Methods: A cross sectional, case-control study conducted on patients with (100 cases) or without (100 controls) type 2 diabetes. The data regarding detailed history, physical examination, Brachial and ankle systolic blood pressures and Routine investigations were recorded, tabulated and statistically analyzed using appropriate statistical tools.
Result: The prevalence of low ABI was significantly higher in diabetics (16%) in comparison with non-diabetic controls (4%) (p<0.05). PAD was more common among women (11.2%) compared to men (6.8%). The mean hsCRP for the study group was 6.51 ± 1.02 significantly higher than the control group 1.74 ± 0.78 (p<0.05).
Conclusions: Changes in CRP levels provide cardiovascular risk prediction, and may be useful to refine cardiovascular risk stratification in high-risk patients with type 2 diabetes mellitus.
- Article View: 66
- PDF Download: 92